Cervical Ripening Clinical Trial
Official title:
Misoprostol Versus Effox (Individually or in Combination) as Cervical Ripening Agent Prior to 1st Trimesteric Surgical Evacuation
NCT number | NCT02738177 |
Other study ID # | 17480 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | April 9, 2016 |
Last updated | April 13, 2016 |
Start date | November 2015 |
Ninety healthy pregnant women candidate for surgical evacuation after confirming 1st trimester pregnancy loss were enrolled in the study. They were randomized in three groups; misoprostol group in which 30 candidates were receive 2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation, Effox group in which 30 candidates were received 2 tablets of Effox (i.e 40 mg) 4 hrs prior to surgical evacuation & combination therapy group in which 30 candidates were received 1 tablets of misoprostol 200ug & 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation. For all participants, the route of administration was the intravaginal route 1ry outcomes included cervical consistency & dilatation immediately before the procedure. 2ry outcomes included total duration of the operation and the occurrence of drug-related side effects
Status | Recruiting |
Enrollment | 90 |
Est. completion date | |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - healthy pregnant women candidate for surgical evacuation - 1st trimesteric pregnancy loss with gestational age 12 weeks or less (diagnosis was confirmed using transvaginal ultrasound according to the following criteria: Crown-rump length {CRL} of 7 mm or more and no heartbeat, Mean sac diameter {MSD} of 25 mm or more and no embryo, absence of embryo with heartbeat 2 wk or more after a scan that showed a gestational sac without a yolk sac and absence of embryo with heartbeat 11 days or more after a scan that showed a gestational sac with a yolk sac) - closed and firm cervix Exclusion Criteria: - evidence suggesting spontaneous onset of abortion (vaginal bleeding or and uterine cramps), previous trial to induce abortion or the use of any cervical ripening agent during the current pregnancy, presence or suspicion of septic abortion (fever > 38 degree Centigrade, offensive vaginal discharge & leukocytosis), Uterine anomalies or history of any cervical surgery or manipulation. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Egypt | Kasr Elainy Hospital (Cairo University) | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | cervical dilatation | tested by the number of the largest Hegar's dilator passed without resistance | 4 hours after receiving the drug | Yes |
Secondary | misoprostol side effects | high temperature (38 degree centigrade or more) and severe abdominal pain. | since receiving the drug till 6 hours postoperative | Yes |
Secondary | effox side effects | headache and low blood pressure | since receiving the drug till 6 hours postoperative | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04949633 -
Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening
|
Phase 3 | |
Withdrawn |
NCT00953641 -
Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy
|
Phase 3 | |
Completed |
NCT01127581 -
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
|
Phase 3 | |
Completed |
NCT00374621 -
Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate
|
N/A | |
Completed |
NCT02732522 -
Comparison Between Vaginal and Sublingual Misoprostol 50 µg for Cervical Ripening Prior to Induction of Labor
|
Phase 4 | |
Recruiting |
NCT05864326 -
Heated Saline in Cervical Balloon for Labor Induction, a RCT
|
N/A | |
Active, not recruiting |
NCT02975167 -
Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor
|
N/A | |
Completed |
NCT03138252 -
Study of the Effectiveness of Cervical Ripening Balloon With and Without Oxytocin
|
Phase 3 | |
Recruiting |
NCT01720394 -
Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert
|
Phase 4 | |
Completed |
NCT00468520 -
Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial
|
N/A | |
Recruiting |
NCT02762942 -
Comparison of Vaginal Misoprostol Plus Supracervical Balloon Versus Vaginal Misoprostol Alone for Induction of Labor
|
Phase 4 | |
Completed |
NCT01283022 -
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
|
Phase 2 | |
Completed |
NCT00886860 -
The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol
|
Phase 4 | |
Recruiting |
NCT01156948 -
Misoprostol For Nulliparous Women Before Hysteroscopy
|
Phase 3 | |
Completed |
NCT00504465 -
Combined Agent Randomized Trial of Induction of Labor
|
N/A | |
Completed |
NCT01428037 -
Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor
|
Phase 3 | |
Not yet recruiting |
NCT00815542 -
Induction of Labor in Oligohydramnios
|
Phase 3 | |
Completed |
NCT01170819 -
Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening.
|
Phase 4 | |
Completed |
NCT00346840 -
Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour
|
Phase 2 | |
Completed |
NCT00442663 -
Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction
|
N/A |